Integra LifeSciences (IART) director Jeffrey Graves receives 17,700 RSU award

Rhea-AI Filing Summary

GRAVES JEFFREY A reported acquisition or exercise transactions in this Form 4 filing.

INTEGRA LIFESCIENCES HOLDINGS CORP director Jeffrey A. Graves received a grant of 17,700 Restricted Stock Units (RSUs). The award was made on May 7, 2026 under the company’s Fifth Amended and Restated 2003 Equity Incentive Plan, at a grant price of $0.00 per unit.

Each RSU represents a contingent right to receive one share of Integra LifeSciences common stock, so the grant covers 17,700 underlying shares. The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. Following this grant, Graves holds 17,700 RSUs directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GRAVES JEFFREY A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	17,700	$0.00	--

Holdings After Transaction: Restricted Stock Units — 17,700 shares (Direct, null)

Footnotes (1)

1. Grant of restricted stock units (RSUs) pursuant to the Integra LifeSciences Holdings Corporation (IART) Fifth Amended and Restated 2003 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of IART common stock. RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026.

Key Figures

RSUs granted: 17,700 units Grant price: $0.00 per unit Underlying shares: 17,700 shares +2 more

5 metrics

RSUs granted 17,700 units Restricted Stock Units awarded May 7, 2026

Grant price $0.00 per unit RSU award under equity incentive plan

Underlying shares 17,700 shares Each RSU equals one common share

Post-grant RSU holdings 17,700 units Total RSUs held directly after transaction

Vesting schedule One year after May 7, 2026 RSUs vest in full on one-year anniversary

Key Terms

Restricted Stock Units, RSUs, Equity Incentive Plan, contingent right, +1 more

5 terms

Restricted Stock Units financial

"Grant of restricted stock units (RSUs) pursuant to the Integra LifeSciences Holdings Corporation..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Each RSU represents a contingent right to receive one share of IART common stock."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Equity Incentive Plan financial

"pursuant to the Integra LifeSciences Holdings Corporation (IART) Fifth Amended and Restated 2003 Equity Incentive Plan, as amended."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

contingent right financial

"Each RSU represents a contingent right to receive one share of IART common stock."

vesting financial

"RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAVES JEFFREY A

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/07/2026		A		17,700		(2)	(2)	Common Stock	17,700	$0	17,700	D

Explanation of Responses:

1. Grant of restricted stock units (RSUs) pursuant to the Integra LifeSciences Holdings Corporation (IART) Fifth Amended and Restated 2003 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of IART common stock.

2. RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026.

Remarks:

	/s/ Michael D. Hutchinson; Attorney-in-Fact for Jeffrey Alan Graves	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did INTEGRA LIFESCIENCES (IART) report for Jeffrey A. Graves?

Jeffrey A. Graves received a grant of 17,700 Restricted Stock Units. The RSUs were awarded on May 7, 2026 under Integra LifeSciences’ Fifth Amended and Restated 2003 Equity Incentive Plan as part of his director compensation.

How many INTEGRA LIFESCIENCES (IART) RSUs were granted to Jeffrey A. Graves and what do they represent?

He was granted 17,700 Restricted Stock Units. Each RSU represents a contingent right to receive one share of Integra LifeSciences common stock, so the grant corresponds to 17,700 underlying shares if the units eventually settle in stock.

When do Jeffrey A. Graves’s INTEGRA LIFESCIENCES (IART) RSUs vest?

The RSUs vest in full on the one-year anniversary of the grant date of May 7, 2026. This means the entire award is scheduled to vest together after that one-year period, rather than in multiple installments.

Did Jeffrey A. Graves pay anything for his INTEGRA LIFESCIENCES (IART) RSU grant?

No cash payment was required for this RSU grant. The Form 4 shows a transaction price of $0.00 per unit, reflecting a typical equity compensation award rather than an open-market purchase of shares.

How many INTEGRA LIFESCIENCES (IART) RSUs does Jeffrey A. Graves hold after this transaction?

After this grant, Jeffrey A. Graves holds 17,700 Restricted Stock Units directly. The filing indicates this post-transaction balance, which matches the full size of the award reported in the Form 4.

Under which plan were Jeffrey A. Graves’s INTEGRA LIFESCIENCES (IART) RSUs granted?

The RSUs were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended. This plan governs equity-based compensation such as restricted stock units for eligible participants.